UVC Partners has backed a $13.5m round that came four years after the diagnostic technology spinout of LMU secured a series B featuring UnternehmerTUM.
GNA Biosolutions, a Germany-based molecular diagnostics technology spinout of Ludwig-Maximilans-Universität München, has completed a $13.5m series C round backed by venture capital firm UVC Partners.
UVC Partners, the investment affiliate of Technical University Munich’s tech transfer arm UnternehmerTUM, participated alongside industrial product manufacturer Robert Bosch’s corporate venturing arm, Robert Bosch Venture Capital (RBVC).
The round further included GreyBird Ventures, Occident, Wachstumsfonds Bayern, SHS Gesellschaft für Beteiligungsmanagement, Mey Capital Matrix, KfW and Btov Partners.
GNA provides technology used by clinical laboratories to detect infectious diseases. Its platform provides molecular diagnostic by leveraging Pulse Controlled Amplification technology, which captures nucleic acids from clinical samples.
Tom Miller, partner at GreyBird Ventures, has been appointed chairman of GNA.
RBVC previously led the company’s $6.6m series B round in 2015, investing alongside KfW, SHS Gesellschaft für Beteiligungsmanagement, Btov Partners, Mey Capital Matrix and UnternehmerTUM.
Mey Capital Matrix and…
